SIFI

SIFI Receives European Commission Approval for AKANTIOR®

📌 We’re excited to announce that SIFI’s AKANTIOR® has been approved by the European Commission for the treatment of acanthamoeba keratitis (AK)! This is the first and only drug approved for this ultra-rare, sight-threatening disease. After 15 years of dedicated research, patients in Europe now have access to an approved, effective treatment. A huge thanks to everyone involved in making this milestone possible. Together, we're advancing eye care and making a difference in patients' lives. Link to press release: https://lnkd.in/dHqYDyqb #AKTreatment #RareDiseases #SIFI #Ophthalmology #Innovation

Tifiamo per te!!!🥇🥇

Dream big and make it a reality with SIFI at ESCRS in Barcelona!  At SIFI, we've imagined the invisible – then transformed it into reality. We’re driven by our team’s skill, dedication and determination – and we've been working for years to always be at the forefront of the field.    Join us this September 6–10 to discover how our visionary thinking is stretching the boundaries of eye surgery. While at ESCRS, make sure you don’t miss out on a special event celebrating SIFI’s journey in eye surgery. Head to Booth G11/G25 at 12pm on Saturday 7th to hear expert insights from leading KOLs. 

ESCRS countdown has started. See you in Barcelona from September 6th to 10th Don’t miss our scientific meetings and come to visit us at the booth 7G25!!

Breaking Eye News from SIFI ! The Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA) has given a positive opinion on Orphan Drug Designation (ODD) for polihexanide in treating fungal keratitis. This severe infection of the cornea, caused by fungi such as Fusarium, Aspergillus, and Candida species, is a major cause of ocular morbidity and unilateral blindness worldwide. Although rare, fungal keratitis can result in significant vision loss if not promptly treated. Currently, there are no approved treatments for this condition in Europe, Japan, Asia, and most other regions globally #orphandrug #raredisease #ophthalmology Read more: https://lnkd.in/dStWhkRF

Seconda giornata al XXII Congresso SICSSO 2024 e siamo soddisfatti: - Best Paper alla Dott.ssa Franch per la sua relazione dal titolo: PHMB 0.08% and Acanthamoeba keratitis: our experience - interesse sempre alto al nostro simposio che ha trattato tematiche sempre attuali: Target pressorio e rispetto della superficie oculare. Un grazie a tutti i nostri relatori e al Congresso SICSSO

Comparto el artículo publicado hoy en El País de España acerca de la keratitis por acanthamoeba, como afecta a quienes padecen esta infección y el desarrollo del producto para su tratamiento hecho por Sifi. Innovación, Desarrollo, Liderazgo!